Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRIO: Romosozumab vs Denosumab on Coronary Atherosclerosis in Postmenopausal Osteoporosis
2025-522592-29-00Phase 4Authorised
- Sponsor
- IRCCS Ospedale Galeazzi-Sant'Ambrogio
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in osteoporosis comparing Romosozumab arm with Denosumab arm (2 arms). Primary endpoint: Primary: Change in coronary CT score (CCTA-Leaman) at 12 months. Planned start Feb 2026; status: authorised.
02
Drugs
romosozumabdenosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2025-522592-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522592-29-00.